<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy of low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> given as 10 mg sub-cutaneously 12 hourly for 2 weeks and repeated at 2 to 3 weekly intervals was evaluated prospectively in 15 consecutive patients of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> over a 3 year period </plain></SENT>
<SENT sid="1" pm="."><plain>Response to therapy was assessed clinically and by haematological parameters including bone marrow examination </plain></SENT>
<SENT sid="2" pm="."><plain>No patient achieved complete remission </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients responded partially </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients transformed into <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, the results of therapy were disappointing as <z:hpo ids='HP_0000001'>all</z:hpo> the 15 patients died within 6 months of diagnosis </plain></SENT>
</text></document>